View Clinical Trial (Medical Research Study)

Comparison of the Alpha-2 Agonists for Prevention of Intraocular Pressure Elevation After Selective Laser Trabeculoplasty - NCT00567411-20307(Clinical Trial 192948)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Washington
State:  
DC
Zip Code: 20307
Conditions: Glaucoma - Ocular Hypertension
Purpose: The purpose of the study is to compare the safety and efficacy of two drops used to lower eye pressure when given prior to a glaucoma laser procedure.
Study summary: This is a prospective randomized double blind trial of patients undergoing selective laser trabeculoplasty for primary open angle glaucoma and ocular hypertension. Enrolled patients are randomized to receive one drop of brimonidine 0.1% in one eye and one drop of apraclonidine 0.5% in the fellow eye. The trabecular meshwork in both eyes of each enrolled patient is treated 360 degrees at the same sitting. Intraocular pressure is measured in each eye one hour before applying the study medications and at one hour and one week after laser surgery.
Criteria: Inclusion Criteria: - male or female, at least 18 years of age - Open Angle Glaucoma with inadequate intraocular pressure (IOP) control or evidence of progression (based on optic nerve head appearance and/or visual field changes) despite current medical therapy - Ocular Hypertension requiring lowering of IOP - ability to understand and provide informed consent to participate in this study and willingness to follow study instructions and likely to complete all required visits Exclusion Criteria: - inability to understand and provide informed consent to participate in this study - inability/unwillingness to follow study instructions and complete all required visits - Documented allergy to either brimonidine or iopidine - Angle Closure Glaucoma - Congenital/Juvenile Glaucoma - Neovascular Glaucoma - Active uveitis
Study is available at: Walter Reed Army Medical Center
Washington, DC 20307
United States

Primary Contact:
Vladimir S Yakopson, MD
Email: vladimir.yakopson@na.amedd.army.mil
Phone: 202-782-6965

Secondary Contact:
Vladimir S Yakopson, MD
Email: vladimir.yakopson@na.amedd.army.mil
Phone: 202-782-6965
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 22, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.